Literature DB >> 25697366

Oligoclonal bands and increased cytokine levels in idiopathic intracranial hypertension.

Güneş Altıokka-Uzun1, Erdem Tüzün2, Esme Ekizoğlu3, Canan Ulusoy2, Sibel Yentür4, Murat Kürtüncü3, Güher Saruhan-Direskeneli4, Betül Baykan3.   

Abstract

OBJECTIVES: The pathogenesis of idiopathic intracranial hypertension (IIH) is currently unknown and there are speculations about the contribution of some immunologic factors. The aim of this study is to investigate the presence of oligoclonal bands (OCBs) and cerebrospinal fluid (CSF) and/or serum cytokine levels in patients with IIH.
METHODS: Patients fulfilling revised diagnostic criteria for IIH were included. Their demographic, clinical, ophthalmologic and laboratory features were examined. Serum and CSF samples were detected by isoelectric focusing and immunoblotting for OCBs. The samples of IIH patients and control groups were investigated by ELISA for cytokine levels.
RESULTS: We detected OCBs in eight (30.77%) patients diagnosed with IIH. There were no other obvious clinical and laboratory differences of IIH profiles between the patients with and without OCBs, but frequency of vision loss was significantly higher in the group with OCBs in comparison to OCB negatives (p = 0.038). Patients with IIH had highly elevated TNF-α, IFN-γ, IL-4, IL-10, IL-12, IL-17 in their sera compared to patients with multiple sclerosis (MS) and healthy controls. Furthermore, all cytokines except TNF-α in the CSF were found significantly higher in IIH patients compared to MS controls.
CONCLUSION: The presence of OCBs and elevated cytokine levels in IIH patients may support an immunologic background in the pathophysiological pathway of this disorder. © International Headache Society 2015.

Entities:  

Keywords:  Oligoclonal bands; cytokine; idiopathic intracranial hypertension; immunology; vision loss

Mesh:

Substances:

Year:  2015        PMID: 25697366     DOI: 10.1177/0333102415570762

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Glial and neuronal antibodies in patients with idiopathic intracranial hypertension.

Authors:  Güneş Altıokka-Uzun; Ece Erdağ; Betül Baykan; John Tzartos; Duygu Gezen-Ak; Bedia Samancı; Erdinç Dursun; Paraskevi Zisimopoulou; Katerina Karagiorgou; Christos Stergiou; Erdi Şahin; Esme Ekizoğlu; Murat Kürtüncü; Erdem Tüzün
Journal:  Neurol Sci       Date:  2017-07-21       Impact factor: 3.307

Review 2.  Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects.

Authors:  Parunyou Julayanont; Amputch Karukote; Doungporn Ruthirago; Deepa Panikkath; Ragesh Panikkath
Journal:  J Pain Res       Date:  2016-02-19       Impact factor: 3.133

3.  Infectious and inflammatory disorders might increase the risk of developing idiopathic intracranial hypertension - a national case-control study.

Authors:  Anna Sundholm; Sarah Burkill; Elisabet Waldenlind; Shahram Bahmanyar; A Ingela M Nilsson Remahl
Journal:  Cephalalgia       Date:  2020-05-25       Impact factor: 6.292

4.  Pseudotumor Cerebri Syndrome Without Headache in an Obese Male With Eight Restricted Cerebrospinal Fluid (CSF) Oligoclonal Bands: A Case Report.

Authors:  Muhammad Ismail Khalid Yousaf; Ping Shi; Rolando M Cordoves Feria; Mohammad Ravi Ghani; David A Robertson
Journal:  Cureus       Date:  2022-02-08

Review 5.  Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases.

Authors:  Keira A Markey; Maria Uldall; Hannah Botfield; Liam D Cato; Mohammed A L Miah; Ghaniah Hassan-Smith; Rigmor H Jensen; Ana M Gonzalez; Alexandra J Sinclair
Journal:  J Pain Res       Date:  2016-04-19       Impact factor: 3.133

6.  Intrathecal T-cell clonal expansions in patients with multiple sclerosis.

Authors:  Alessandra de Paula Alves Sousa; Kory R Johnson; Richard Nicholas; Sam Darko; David A Price; Daniel C Douek; Steven Jacobson; Paolo A Muraro
Journal:  Ann Clin Transl Neurol       Date:  2016-04-20       Impact factor: 4.511

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.